What is the current Oxford Biomedica market capitalization?
The current market capitalization of Oxford Biomedica is 317.67 M GBP.
Oxford Biomedica Market capitalization 2024
Oxford Biomedica Market capitalization
317.67 M GBP
Oxford Biomedica Dividend yield
Ticker
OXB.L
ISIN
GB00BDFBVT43
WKN
A2JLRX
In 2024, Oxford Biomedica's market cap stood at 317.67 M GBP, a -27.68% increase from the 439.23 M GBP market cap in the previous year.
The Oxford Biomedica Market capitalization history
| YEAR | REVENUE (undefined GBP) | GROSS MARGIN (%) | NET INCOME (undefined GBP) |
|---|---|---|---|
| 2027e | 245.94 | 16,15 | 29.07 |
| 2026e | 211.36 | 18,80 | -7.11 |
| 2025e | 169.34 | 23,46 | -26.17 |
| 2024e | 133.27 | 29,81 | -41.25 |
| 2023 | 89.54 | 44,37 | -157.49 |
| 2022 | 139.99 | 49,42 | -39.16 |
| 2021 | 142.8 | 57,87 | 19.01 |
| 2020 | 87.73 | 52,52 | -6.25 |
| 2019 | 64.06 | 44,24 | -16.07 |
| 2018 | 66.78 | 65,91 | 7.54 |
| 2017 | 37.59 | 50,94 | -9.02 |
| 2016 | 27.78 | 57,39 | -16.64 |
| 2015 | 15.91 | 63,30 | -13.02 |
| 2014 | 13.62 | 67,57 | -8.66 |
| 2013 | 5.38 | 78,81 | -11.1 |
| 2012 | 7.76 | 91,37 | -8.73 |
| 2011 | 7.72 | 92,75 | -12.63 |
| 2010 | 11.15 | 105,38 | -10.29 |
| 2009 | 19.12 | 97,70 | -3.52 |
| 2008 | 18.39 | 92,99 | -10.04 |
| 2007 | 7.22 | 93,77 | -15.29 |
| 2006 | 0.76 | 100,00 | -17.63 |
| 2005 | 0.82 | 4844,76 | -9.09 |
| 2004 | 0.5 | 7945,40 | -10.61 |
Oxford Biomedica Aktienanalyse
What does Oxford Biomedica do?
Oxford BioMedica PLC is a biopharmaceutical company based in Oxford, England. The company was founded in 1995 and has since become a leading provider of gene therapy products. The company's business model is to develop, produce, and market gene therapies for rare diseases and cancer. Oxford BioMedica utilizes modern technologies, such as viral vectors, to introduce genetic material into diseased cells and correct their function. One of the company's main areas of focus is the development of gene therapies for rare diseases. Oxford BioMedica has several promising products in this field, including gene therapies for metabolic disorders, muscular diseases, and eye diseases. Another important area for the company is the development of cancer immunotherapies. Oxford BioMedica is working on the development of gene therapies that activate the body's immune system to specifically target cancer cells. Among the products that Oxford BioMedica has already brought to market is the gene therapy product Strimvelis, which is used to treat severe combined immunodeficiency (SCID). Through treatment with Strimvelis, children with SCID can lead a normal life and are no longer confined to sterile environments. Another well-known product from Oxford BioMedica is the gene therapy product OXB-102, which is being tested in phase III clinical trials for the treatment of Parkinson's disease. In this therapy, a viral vector is used to correct a genetic mutation in the affected brain cells and alleviate the symptoms of Parkinson's. In recent years, Oxford BioMedica has also formed significant partnerships with major pharmaceutical and biotech companies such as Novartis, Sanofi, and Bioverativ to further develop and bring its gene therapy technology and products to market. Overall, Oxford BioMedica is a leading company in the field of gene therapy. With a strong pipeline of promising products and significant partnerships with the pharmaceutical industry, the company is well positioned to continue growing and contribute to the cure of diseases. Oxford Biomedica ist eines der beliebtesten Unternehmen auf Eulerpool.com.Market capitalization Details
Exploring Oxford Biomedica's Market Capitalization
Oxford Biomedica's market capitalization represents the total dollar market value of the company’s outstanding shares of stock. It is calculated by multiplying the company's shares outstanding by the current market price of one share. This metric is a vital indicator of a company’s size, strength, and overall market value.
Year-to-Year Comparison
A yearly comparison of Oxford Biomedica's market capitalization provides investors and analysts insights into its growth and valuation trends. An increase signifies market confidence and business expansion, while a decrease may point towards declining market value or business contractions.
Impact on Investments
Oxford Biomedica's market capitalization plays a pivotal role in investment decisions. It aids investors in assessing the company's risk and return profiles. Larger companies are often considered more stable but may offer lower growth potential, while smaller companies might offer significant growth prospects but come with higher risk.
Interpreting Market Capitalization Fluctuations
Variations in Oxford Biomedica’s market capitalization can be attributed to several factors, including changes in stock price, outstanding shares, and market sentiment. Understanding these fluctuations helps investors evaluate the company's current standing and future potential in the competitive landscape.
Frequently Asked Questions about Oxford Biomedica Stock
What is market capitalization?
The market capitalization (German: Marktkapitalisierung, English: market capitalization, abbreviated as market cap, also known as stock exchange capitalization or market value) is the calculated total value of all shares of a publicly traded company like Oxford Biomedica.
How has the market capitalization of Oxford Biomedica developed in recent years?
The market capitalization of Oxford Biomedica has increased/decreased by -27.68% compared to the previous year.
What does market capitalization mean for investors?
The market capitalization of a company reflects the current market consensus on the value of the equity of a publicly traded company.
Why is market capitalization an important indicator for investors?
The market capitalization of a company reflects the current market consensus on the value of a publicly traded company's equity. It is determined by the supply and demand for the company's shares. Market capitalization is thus significantly influenced by expectations in the stock market regarding the future earnings power of the company, and as such, it can undergo significant fluctuations.
Why does the market capitalization fluctuate?
The market capitalization fluctuates along with the stock price, as the market capitalization is calculated based on the current price and the number of outstanding shares.
What role does market capitalization play in the valuation of Oxford Biomedica?
In order to compare the value of companies, it is helpful to consider not only the market capitalization but also the net debt of a company. A potential buyer of the entire company would also acquire the debts of the company. The enterprise value is the total value of a company or a stock corporation. The net financial indebtedness of the company is added to the market capitalization.
Does the market capitalization influence the performance of Oxford Biomedica?
There is no verifiable long-term evidence or study that stocks with a specific market capitalization (whether Mega/Large/Mid/Small Cap) would consistently yield significantly higher returns than others. There are occasional small studies (few stocks, short investment period) suggesting that certain classes may perform better or have higher risk, but none of them are 1. conclusive (cause-effect relationship is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).
Does the market capitalization of Oxford Biomedica have an influence on indices?
Some stock indices use market capitalization as index weighting. Stocks with a higher market capitalization are also weighted higher in the index. This is in contrast to equally weighted indices (all stocks have the same weighting) and free float weighted indices (market capitalization weighting, but only with the number of shares in free float).
How much dividend does Oxford Biomedica pay?
Over the past 12 months, Oxford Biomedica paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Oxford Biomedica is expected to pay a dividend of 0 GBP.
What is the dividend yield of Oxford Biomedica?
The current dividend yield of Oxford Biomedica is .
When does Oxford Biomedica pay dividends?
Oxford Biomedica pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Oxford Biomedica?
Oxford Biomedica paid dividends every year for the past 0 years.
What is the dividend of Oxford Biomedica?
For the upcoming 12 months, dividends amounting to 0 GBP are expected. This corresponds to a dividend yield of 0 %.
In which sector is Oxford Biomedica located?
Oxford Biomedica is assigned to the 'Health' sector.
Wann musste ich die Aktien von Oxford Biomedica kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Oxford Biomedica from 6/8/2024 amounting to 0 GBP, you needed to have the stock in your portfolio before the ex-date on 6/8/2024.
When did Oxford Biomedica pay the last dividend?
The last dividend was paid out on 6/8/2024.
What was the dividend of Oxford Biomedica in the year 2023?
In the year 2023, Oxford Biomedica distributed 0 GBP as dividends.
In which currency does Oxford Biomedica pay out the dividend?
The dividends of Oxford Biomedica are distributed in GBP.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
The Oxford Biomedica stock can be added to a savings plan with the following providers: Trade Republic
Andere Kennzahlen von Oxford Biomedica
Our stock analysis for Oxford Biomedica Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Oxford Biomedica Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
- Oxford Biomedica Revenue
- Oxford Biomedica Net Income
- Oxford Biomedica P/E
- Oxford Biomedica P/S
- Oxford Biomedica EBIT
- Oxford Biomedica Dividend
- Oxford Biomedica Stocks
- Oxford Biomedica Market capitalization
- Oxford Biomedica Debt
- Oxford Biomedica Liabilities
- Oxford Biomedica Equity
- Oxford Biomedica AAQS
- Oxford Biomedica Employees
- Oxford Biomedica ROE
- Oxford Biomedica ROA
- Oxford Biomedica ROCE
